These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31502421)

  • 1. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
    Gupta A; Pouliquen I; Austin D; Price RG; Kempsford R; Steinfeld J; Bradford ES; Yancey SW
    Pediatr Pulmonol; 2019 Dec; 54(12):1957-1967. PubMed ID: 31502421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
    J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
    Albers FC; Papi A; Taillé C; Bratton DJ; Bradford ES; Yancey SW; Kwon N
    Respir Res; 2019 Jul; 20(1):169. PubMed ID: 31362741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
    Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN; Cargill SM; Waineo MF; Wolford AL
    Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
    Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
    J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
    Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
    N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.